Sun Pharma Q2 profit plunges 36% on exceptional charges despite revenue growth

Sun Pharmaceutical Industries reported a 36.4% year-on-year (YoY) decline in consolidated net profit to ₹1,988.5 crore for the September quarter, weighed down by exceptional charges of ₹1,268.8 crore related to its acquisition of Organon and a settlement in an antitrust litigation.Excluding the exceptional items, adjusted net profit stood at ₹3,162 crore. Revenue from operations, however, grew nearly 12% YoY to ₹16,198.7 crore.“Our performance during the quarter was driven by strong momentum in India, Emerging Markets and Rest of World,” managing director Kirti Ganorkar said.The company’s U.S. formulation sales declined 8.2% to $455 million during Q2 FY27, accounting for around 27% of its consolidated sales. Published - October 30, 2026 09:50 pm IST